TearScience has announced a 50% price cut, effective immediately, on the single-use activators used with the LipiFlow treatment platform for meibomian gland disease (MGD). The move is one component of an overall strategy to make the LipiFlow and LipiView Technologies more accessible to eye care professionals, who can then, in turn, use them to evaluate and intervene earlier in MGD for the benefit of the millions of individuals suffering from this chronic and progressive obstructive gland disease, according to a company news release.
After recent unprecedented growth in use of its LipiFlow technology, TearScience is achieving the economies of scale necessary to reorganize and expand its supply and manufacturing capabilities. Furthermore, TearScience brought on board a new management team with a renewed mission to meet a market need of technology and treatment accessibility. Earlier this year, TearScience lowered the price of its technologies and removed imaging fees.
“By enacting these changes, we are answering the market’s demand for greater accessibility to our core technologies so that eye care professionals can accurately evaluate MGD early in its course and intervene in this progressive disease,” Joseph Boorady, OD, CEO of TearScience, said in the news release. “We are proud partners with the eye care community, and this latest move is driven by a desire to facilitate greater physician and patient accessibility to evaluative testing and truly effective treatment. We look forward to identifying additional ways we can partner with the eye care community to improve access.”
Now, with the strategy changes and price modifications being announced, TearScience is supporting eye care professionals in the early evaluation and treatment of patients with MGD. LipiFlow applies heat to the inner eyelid and pressure to the outer eyelid during an in-office procedure. It is the only electronic device cleared by the FDA for treatment of MGD. In multiple clinical studies, LipiFlow has consistently been shown to significantly improve mean meibomian gland secretions and reduce mean dry eye symptoms to approximately half of the pre-procedure level. LipiFlow has been used in 80,000 procedures since its launch.
“The technologies available to evaluate and treat MGD are an essential part of my clinical practice,” Preeya Gupta, MD, said in the news release. “Not only is MGD a very important cause of DED, it is also a chronic and progressive disease that can lead to loss of gland function, and, therefore, the inability to have a healthy tear film. To have meaningful outcomes for patients, we prefer to diagnose it early so we can intervene before the disease course advances too far, just like for other progressive diseases.”